Doctor Désirée Deandreis

Dr Désirée Deandreis is a nuclear medicine physician, Head of the Nuclear Medicine Department at Gustave Roussy since 2023, and Associate Professor at the University of Turin, Italy.

She graduated in medicine from the University of Turin and completed part of her specialisation in nuclear medicine with a focus on oncology at Gustave Roussy. From 2006 to 2016, she worked as a nuclear medicine physician at the Institute, with a particular interest in endocrine and prostate tumours. During this period, she also completed a research fellowship on thyroid cancer at Memorial Sloan Kettering Cancer Center in New York (2010–2011).

Between 2016 and 2022, Dr Deandreis led the postgraduate specialisation programme in nuclear medicine at the University of Turin and, from 2019 to 2022, headed the nuclear medicine department at the university hospital Città della Salute e della Scienza, also in Turin. In 2023, she returned to Gustave Roussy to lead its Nuclear Medicine Department.

Author of over 140 scientific publications and principal investigator in numerous early- and late-phase clinical trials, Dr Deandreis focuses her research on a theranostic approach to nuclear medicine, combining diagnostic imaging and targeted therapy. She is particularly interested in the use of molecular imaging with PET tracers as true biomarkers, with the aim of improving understanding of tumour biology and optimising treatment strategies, especially with radioligand therapy.

She is also developing expertise in the application of artificial intelligence to advanced image analysis and radiobiology, to better understand the mechanisms of radioresistance and toxicity associated with radioligand therapy. In 2023, she established the Phase I – First-in-Human Unit in Nuclear Medicine at Gustave Roussy, in collaboration with the DITEP.

Finally, Dr Deandreis is an active contributor to the educational programme of the European Association of Nuclear Medicine (EANM).